388 related articles for article (PubMed ID: 25381666)
1. Co-culture system of human salivary gland epithelial cells and immune cells from primary Sjögren's syndrome patients: an in vitro approach to study the effects of Rituximab on the activation of the Raf-1/ERK1/2 pathway.
Lisi S; Sisto M; D'Amore M; Lofrumento DD
Int Immunol; 2015 Apr; 27(4):183-94. PubMed ID: 25381666
[TBL] [Abstract][Full Text] [Related]
2. Chronic inflammation enhances NGF-β/TrkA system expression via EGFR/MEK/ERK pathway activation in Sjögren's syndrome.
Lisi S; Sisto M; Ribatti D; D'Amore M; De Lucro R; Frassanito MA; Lorusso L; Vacca A; Lofrumento DD
J Mol Med (Berl); 2014 May; 92(5):523-37. PubMed ID: 24557415
[TBL] [Abstract][Full Text] [Related]
3. TLR2 signals via NF-κB to drive IL-15 production in salivary gland epithelial cells derived from patients with primary Sjögren's syndrome.
Sisto M; Lorusso L; Lisi S
Clin Exp Med; 2017 Aug; 17(3):341-350. PubMed ID: 27260411
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic dysregulation in salivary glands from patients with primary Sjögren's syndrome may be ascribed to infiltrating B cells.
Thabet Y; Le Dantec C; Ghedira I; Devauchelle V; Cornec D; Pers JO; Renaudineau Y
J Autoimmun; 2013 Mar; 41():175-81. PubMed ID: 23478041
[TBL] [Abstract][Full Text] [Related]
5. Rituximab-mediated Raf kinase inhibitor protein induction modulates NF-κB in Sjögren syndrome.
Sisto M; Lisi S; D'Amore M; Lofrumento DD
Immunology; 2014 Sep; 143(1):42-51. PubMed ID: 24655025
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab.
Jazirehi AR; Vega MI; Chatterjee D; Goodglick L; Bonavida B
Cancer Res; 2004 Oct; 64(19):7117-26. PubMed ID: 15466208
[TBL] [Abstract][Full Text] [Related]
7. Towards personalised treatment in primary Sjögren's syndrome: baseline parotid histopathology predicts responsiveness to rituximab treatment.
Delli K; Haacke EA; Kroese FG; Pollard RP; Ihrler S; van der Vegt B; Vissink A; Bootsma H; Spijkervet FK
Ann Rheum Dis; 2016 Nov; 75(11):1933-1938. PubMed ID: 26757748
[TBL] [Abstract][Full Text] [Related]
8. Cell-specific epigenome-wide DNA methylation profile in long-term cultured minor salivary gland epithelial cells from patients with Sjögren's syndrome.
Charras A; Konsta OD; Le Dantec C; Bagacean C; Kapsogeorgou EK; Tzioufas AG; Pers JO; Bordron A; Renaudineau Y
Ann Rheum Dis; 2017 Mar; 76(3):625-628. PubMed ID: 28093418
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up study.
Carubbi F; Cipriani P; Marrelli A; Benedetto P; Ruscitti P; Berardicurti O; Pantano I; Liakouli V; Alvaro S; Alunno A; Manzo A; Ciccia F; Gerli R; Triolo G; Giacomelli R
Arthritis Res Ther; 2013 Oct; 15(5):R172. PubMed ID: 24286296
[TBL] [Abstract][Full Text] [Related]
10. Interleukin (IL)-17-producing pathogenic T lymphocytes co-express CD20 and are depleted by rituximab in primary Sjögren's syndrome: a pilot study.
Alunno A; Carubbi F; Bistoni O; Caterbi S; Bartoloni E; Di Benedetto P; Cipriani P; Giacomelli R; Gerli R
Clin Exp Immunol; 2016 Jun; 184(3):284-92. PubMed ID: 26814615
[TBL] [Abstract][Full Text] [Related]
11. NKp30 Receptor Upregulation in Salivary Glands of Sjögren's Syndrome Characterizes Ectopic Lymphoid Structures and Is Restricted by Rituximab Treatment.
Pontarini E; Sciacca E; Grigoriadou S; Rivellese F; Lucchesi D; Fossati-Jimack L; Coleby R; Chowdhury F; Calcaterra F; Tappuni A; Lewis MJ; Fabris M; Quartuccio L; Bella SD; Bowman S; Pitzalis C; Mavilio D; De Vita S; Bombardieri M
Front Immunol; 2021; 12():706737. PubMed ID: 34594326
[TBL] [Abstract][Full Text] [Related]
12. Salivary gland epithelial cells from patients with Sjögren's syndrome induce B-lymphocyte survival and activation.
Rivière E; Pascaud J; Tchitchek N; Boudaoud S; Paoletti A; Ly B; Dupré A; Chen H; Thai A; Allaire N; Jagla B; Mingueneau M; Nocturne G; Mariette X
Ann Rheum Dis; 2020 Nov; 79(11):1468-1477. PubMed ID: 32843324
[TBL] [Abstract][Full Text] [Related]
13. Differentiation of follicular helper T cells by salivary gland epithelial cells in primary Sjögren's syndrome.
Gong YZ; Nititham J; Taylor K; Miceli-Richard C; Sordet C; Wachsmann D; Bahram S; Georgel P; Criswell LA; Sibilia J; Mariette X; Alsaleh G; Gottenberg JE
J Autoimmun; 2014 Jun; 51():57-66. PubMed ID: 24411167
[TBL] [Abstract][Full Text] [Related]
14. Establishment of a convenient system for the long-term culture and study of non-neoplastic human salivary gland epithelial cells.
Dimitriou ID; Kapsogeorgou EK; Abu-Helu RF; Moutsopoulos HM; Manoussakis MN
Eur J Oral Sci; 2002 Feb; 110(1):21-30. PubMed ID: 11878756
[TBL] [Abstract][Full Text] [Related]
15. FcRL4
Haacke EA; Bootsma H; Spijkervet FKL; Visser A; Vissink A; Kluin PM; Kroese FGM
J Autoimmun; 2017 Jul; 81():90-98. PubMed ID: 28390747
[TBL] [Abstract][Full Text] [Related]
16. Induction of salivary gland epithelial cell injury in Sjogren's syndrome: in vitro assessment of T cell-derived cytokines and Fas protein expression.
Abu-Helu RF; Dimitriou ID; Kapsogeorgou EK; Moutsopoulos HM; Manoussakis MN
J Autoimmun; 2001 Sep; 17(2):141-53. PubMed ID: 11591123
[TBL] [Abstract][Full Text] [Related]
17. Blood and salivary-gland BAFF-driven B-cell hyperactivity is associated to rituximab inefficacy in primary Sjögren's syndrome.
Cornec D; Costa S; Devauchelle-Pensec V; Jousse-Joulin S; Marcorelles P; Berthelot JM; Chiche L; Hachulla E; Hatron PY; Goeb V; Vittecoq O; Saraux A; Pers JO
J Autoimmun; 2016 Feb; 67():102-110. PubMed ID: 26688003
[TBL] [Abstract][Full Text] [Related]
18. The metalloproteinase ADAM17 and the epidermal growth factor receptor (EGFR) signaling drive the inflammatory epithelial response in Sjögren's syndrome.
Sisto M; Lisi S; D'Amore M; Lofrumento DD
Clin Exp Med; 2015 May; 15(2):215-25. PubMed ID: 24664458
[TBL] [Abstract][Full Text] [Related]
19. B7-H4 deficiency in salivary gland of patients with primary Sjögren's syndrome impairs the regulatory effect on T cells.
Li X; Yu D; Yu N; Wang X; Li X; Harris DCH; Wang Y
Int J Rheum Dis; 2017 Apr; 20(4):474-480. PubMed ID: 28217953
[TBL] [Abstract][Full Text] [Related]
20. Alleviating effect of paeoniflorin-6'-O-benzene sulfonate in antigen-induced experimental Sjögren's syndrome by modulating B lymphocyte migration via CXCR5-GRK2-ERK/p38 signaling pathway.
Chen X; Zhang P; Liu Q; Zhang Q; Gu F; Xu S; Körner H; Wu H; Wei W
Int Immunopharmacol; 2020 Mar; 80():106199. PubMed ID: 31955068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
